(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 June 2019 (27.06.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/122166 A1

(51) International Patent Classification:
A61K 38/48 (2006.01) *A61P 21/00* (2006.01)

(21) International Application Number:
PCT/EP2018/086261

(22) International Filing Date:
20 December 2018 (20.12.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17306840.4 20 December 2017 (20.12.2017) EP

(71) Applicant: **IPSEN BIOPHARM LIMITED** [GB/GB]; Unit 9 Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF (GB).

(72) Inventors: **KRUPP, Johannes**; c/o Ipsen Biopharm Limited, Unit 9 Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF (GB). **MAIGNEL-LUDOL, Jacquie**; c/o Ipsen Biopharm Limited, Unit 9 Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF (GB). **PIGNOL, Bernadette**; c/o Ipsen Biopharm Limited, Unit 9 Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF (GB).

(74) Agent: **HOBSON, David James**; Mathys & Squire LLP, The Shard, 32 London Bridge Street, London SE1 9SG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN




FIGURE 3

(57) Abstract: The present invention relates to the treatment of autonomic disorders with a clostridial neurotoxin comprising a H_{cc} domain from a BoNT/B, BoNT/D, BoNT/D-C, BoNT/F or BoNT/G, wherein the dose of the clostridial neurotoxin to be administered to the patient is equivalent to or lower than the dose of BoNT/A that would be used to treat the same autonomic disorder.

WO 2019/122166 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*